Farid Ramy 4

What Happened

• Farid Ramy, a director of Vir Biotechnology (VIR), received equity awards on 2026-05-27 totaling 24,000 shares: an 8,000-share restricted stock unit (RSU) grant and a 16,000-share derivative award. Both awards show an acquisition price of $0.00 (i.e., awarded, not purchased). Per the filing footnotes, the RSUs and the derivative award vest in full on May 27, 2027.

Key Details

• Transaction date: May 27, 2026; acquisition price: $0.00 for each award.
• Awards: 8,000 RSUs (F1); 16,000 derivative award (reported as derivative; footnote indicates stock-option style terms — F3).
• Vesting: Both awards vest in full on May 27, 2027 (F2/F3).
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: Report filed May 28, 2026 (timely relative to the reported May 27, 2026 transaction).
• Transaction code: A = Award/Grant.

Context

• RSUs and derivative awards are common forms of director/employee compensation and do not involve an immediate cash outlay; they generally convert to shares (or become exercisable) upon vesting. This filing reports the grant only—no exercise or sale occurred. The awards vest in one year, at which point Ramy may receive shares or be able to exercise options per the award terms. Awards are informative about compensation but do not by themselves indicate an insider buying or selling signal.